Il regime giuridico del porto di Hong Kong nel sistema dei traffici marittimi internazionali

In forza del suo passato giuridico regolato dal Common law, Hong Kong ha acquisito grande competenza in particolare nell’Arbitrato internazionale al punto che oggi è anche un centro mondiale per la risoluzione delle controversie commerciali. Questo aspetto delle relazioni internazionali è certamente attribuibile al prestigio del porto. Già da due anni la città di Shenzhen ha sottoscritto un accordo con la città di Hong Kong per unire le due Municipalità in una unica grande struttura urbana, allargando quindi a dismisura la “zona franca” di Hong Kong, già ora uno dei principali snodi finanziari mondiali e uno dei centri mondiali del turismo. la Cina punta ad accentrare in questa megalopoli interessi mondali in vari settori, costituendo un autentico motore per lo sviluppo dell’Asia

PoliTo at MULTI-Fake-DetectiVE: Improving FND-CLIP for Multimodal Italian Fake News Detection

The MULTI-Fake-DetectiVE challenge addresses the automatic detection of Italian fake news in a multimodal setting, where both textual and visual components contribute as potential sources of fake content. This paper describes the PoliTO approach to the tasks of fake news detection and analysis of the modality contributions. Our solution turns out to be the best performer on both tasks. It leverages the established FND-CLIP multimodal architecture and proposes ad hoc extensions including sentiment-based text encoding, image transformation in the frequency domain, and data augmentation via back-translation. Thanks to its effectiveness in combining visual and textual content, our solution contributes to fighting the spread of disinformation in the Italian news flow

villas on islands cost effective energy refurbishment in mediterranean coastline houses

Abstract This paper aims to underline the variability of constructions in Mediterranean regions, where different climates, architectural techniques and kinds of building uses determine different optimal energy refurbishments of residential buildings placed on the coastline. More in detail, by considering two different construction technologies (i.e., a lightweight house in reinforced concrete and a massive tuff-made villa), two different climates (Greek coast, climate of Athens and Italian coast, climate of Naples), two cost-optimal energy retrofits are presented. The optimized energy retrofit, performed by coupling transient energy simulations and genetic algorithm for generating improved models, have taken into account all levers of energy efficiency, and thus optimization of building envelope (thermal insulation, reflectance, windows and solar screens), active energy systems (daylight control, HVAC systems for the regulation of indoor conditions) and renewable energy sources at the building scale (namely, solar photovoltaic)

Clinical management of metastatic colorectal cancer in the era of precision medicine

Immunotherapy; Metastatic colorectal cancer; Precision medicineInmunoterapia; Cáncer colorrectal metastásico; Medicina de precisiónImmunoteràpia; Càncer colorectal metastàtic; Medicina de precisióColorectal cancer (CRC) represents approximately 10% of all cancers and is the second most common cause of cancer deaths. Initial clinical presentation as metastatic CRC (mCRC) occurs in approximately 20% of patients. Moreover, up to 50% of patients with localized disease eventually develop metastases. Appropriate clinical management of these patients is still a challenging medical issue. Major efforts have been made to unveil the molecular landscape of mCRC. This has resulted in the identification of several druggable tumor molecular targets with the aim of developing personalized treatments for each patient. This review summarizes the improvements in the clinical management of patients with mCRC in the emerging era of precision medicine. In fact, molecular stratification, on which the current treatment algorithm for mCRC is based, although it does not completely represent the complexity of this disease, has been the first significant step toward clinically informative genetic profiling for implementing more effective therapeutic approaches. This has resulted in a clinically relevant increase in mCRC disease control and patient survival. The next steps in the clinical management of mCRC will be to integrate the comprehensive knowledge of tumor gene alterations, of tumor and microenvironment gene and protein expression profiling, of host immune competence as well as the application of the resulting dynamic changes to a precision medicine-based continuum of care for each patient. This approach could result in the identification of individual prognostic and predictive parameters, which could help the clinician in choosing the most appropriate therapeutic program(s) throughout the entire disease journey for each patient with mCRC.Fortunato Ciardiello was supported by a grant from Regione Campania (I-Cure Research Project Cup 21C17000030007). Andres Cervantes was supported by grants from the Instituto de Salud Carlos III (PI18/01909 and PI21/00689). Fortunato Ciardiello reports institutional research grants from Amgen, Merck KGaA, Merck Sharp & Dohme, Pfizer, Pierre Fabre, Roche, and Servier; and service on advisory boards for Bayer, Merck KGaA, Merck Sharp & Dohme, Pierre Fabre, Roche, and Servier outside the submitted work. Davide Ciardiello reports a travel grant from Sanofi outside the submitted work. Stefania Napolitano reports honoraria from Bristol Myers Squibb and Novartis outside the submitted work. Josep Tabernero reports advisory board or scientific consultancy fees from Array Biopharma, AstraZeneca, Avvinity, Bayer, Boehringer Ingelheim, Chugai, Daiichi-Sankyo, Roche, Genentech, HalioDX SAS, Hutchison MediPharma International, Ikena Oncology, Inspirna Inc, IQVIA, Lilly, Menarini, Merck KGaA, Merus, Merck Sharp & Dohme, Mirati, Neophore, Novartis, Ona Therapeutics, Orion Biotechnology, Peptomyc, Pfizer, Pierre Fabre, Samsung Bioepis, Sanofi, Seattle Genetics, Scandion Oncology, Servier, SotioBiotech, Taiho, Tessa Therapeutics, and TheraMyc outside the submitted work. Andres Cervantes reports institutional research grants from Genentech, Merck KGaA, Bristol Myers Squibb, Merck Sharp & Dohme, Roche, Beigene, Bayer, Servier, Lilly, Novartis, Takeda, Astellas, Takeda, and Fibrogen; and honoraria or speaker’s fees from Amgen, Merck KGaA, Roche, Bayer, Servier, and Pierre Fabre outside the submitted work. Giulia Martini reports no conflicts of interest

First trimester screening for pre-eclampsia and targeted aspirin prophylaxis: a cost-effectiveness cohort study

Objective: Investigate cost-effectiveness of first trimester pre-eclampsia screening using the Fetal Medicine Foundation (FMF) algorithm and targeted aspirin prophylaxis in comparison with standard care. // Design: Retrospective observational study. // Setting: London tertiary hospital. // Population: 5957 pregnancies screened for pre-eclampsia using the National Institute for Health and Care Excellence (NICE) method. // Methods: Differences in pregnancy outcomes between those who developed pre-eclampsia, term pre-eclampsia and preterm pre-eclampsia were compared by the Kruskal–Wallis and Chi-square tests. The FMF algorithm was applied retrospectively to the cohort. A decision analytic model was used to estimate costs and outcomes for pregnancies screened using NICE and those screened using the FMF algorithm. The decision point probabilities were calculated using the included cohort. // Main outcome measures: Incremental healthcare costs and QALY gained per pregnancy screened. // Results: Of 5957 pregnancies, 12.8% and 15.9% were screen-positive for development of pre-eclampsia using the NICE and FMF methods, respectively. Of those who were screen-positive by NICE recommendations, aspirin was not prescribed in 25%. Across the three groups, namely, pregnancies without pre-eclampsia, term pre-eclampsia and preterm pre-eclampsia there was a statistically significant trend in rates of emergency caesarean (respectively 21%, 43% and 71.4%; P < 0.001), admission to neonatal intensive care unit (NICU) (5.9%, 9.4%, 41%; P < 0.001) and length of stay in NICU. The FMF algorithm was associated with seven fewer cases of preterm pre-eclampsia, cost saving of £9.06 and QALY gain of 0.00006/pregnancy screened. // Conclusions: Using a conservative approach, application of the FMF algorithm achieved clinical benefit and an economic cost saving

Green innovation and income inequality: A complex system analysis.

The objective of this paper is to analyse the relationship between income inequality and environmental innovation. To this end, we use the Economic Fitness and Complexity algorithm to compute an index of green inventive capacity in a panel of 57 countries over the period 1970-2010. The empirical analysis reveals that, on average, inequality is detrimental to countries' capacity to develop complex green technologies. Using non-parametric methods we further articulate this general finding and uncover interesting non-linearities in the relationship between innovation and inequality. [Abstract copyright: © 2022 The Author(s).

Green innovation and income inequality: A complex system analysis.

The objective of this paper is to analyse the relationship between income inequality and environmental innovation. To this end, we use the Economic Fitness and Complexity algorithm to compute an index of green inventive capacity in a panel of 57 countries over the period 1970-2010. The empirical analysis reveals that, on average, inequality is detrimental to countries' capacity to develop complex green technologies. Using non-parametric methods we further articulate this general finding and uncover interesting non-linearities in the relationship between innovation and inequality. [Abstract copyright: © 2022 The Author(s).

Biomarker-Guided Anti-Egfr Rechallenge Therapy in Metastatic Colorectal Cancer

Anticossos monoclonals anti-EGFR; Càncer colorectal metastàticAnticuerpos monoclonales anti-EGFR; Cáncer colorrectal metastásicoAnti-EGFR monoclonal antibodies; Metastatic colorectal cancerThe prognosis of patients with metastatic colorectal cancer (mCRC) who progressed to the first and the second lines of treatment is poor. Thus, new therapeutic strategies are needed. During the last years, emerging evidence suggests that retreatment with anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (MAbs) in the third line of mCRC patients, that have previously obtained clinical benefit by first-line therapy with anti-EGFR MAbs plus chemotherapy, could lead to prolonged survival. The rationale beyond this “rechallenge” strategy is that, after disease progression to first line EGFR-based therapy, a treatment break from anti-EGFR drugs results in RAS mutant cancer cell decay, restoring the sensitivity of cancer cells to cetuximab and panitumumab. In fact, rechallenge treatment with anti-EGFR drugs has shown promising clinical activity, particularly in patients with plasma RAS and BRAF wild type circulating tumor DNA, as defined by liquid biopsy analysis at baseline treatment. The aim of this review is to analyze the current knowledge on rechallenge and to investigate the role of novel biomarkers that can guide the appropriate selection of patients that could benefit from this therapeutic strategy. Finally, we discuss on-going trials and future perspectives.Regione Campania (I-Cure Research Project, Grant number: Cup 21C17000030007), Gruppo Oncologico dell’Italia Meridionale (GOIM)

Green Technology Fitness

[EN] The present study provides an analysis of empirical regularities in the development of green technology. We use patent data to examine inventions that can be traced to the environment-related catalogue (ENV-T ECH ) covering technologies in environmental management, water-related adaptation and climate change mitigation. Further, we employ the Economic Fitness-Complexity (EFC) approach to assess their development and geographical distribution across countries between 1970 and 2010. This allows us to identify three typologies of countries: leaders, laggards and catch-up. While, as expected, there is a direct relationship between GDP per capita and invention capacity, we also document the remarkable growth of East Asia countries that started from the periphery and rapidly established themselves as key actors. This geographical pattern coincides with higher integration across domains so that, while the relative development of individual areas may have peaked, there is now demand for greater interoperability across green technologies.L.N. acknowledges financial support from the Italian Project of National Interest CRISISLAB (MIUR).Sbardella, A.; Perruchas, FDX.; Napolitano, L.; Barbieri, N.; Consoli, D. (2018). Green Technology Fitness. Entropy. 20(10). https://doi.org/10.3390/e20100776S201